REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting
24 Jul 2023
Phase 2Gene TherapyLicense out/in
ROCKVILLE, Md., July 24, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced three presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, taking place in Seattle, Washington from July 28 through August 1, 2023. The presentations will highlight data for ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet AMDAMD, DR and other chronic retinal conditions, including new interim data from the pharmacodynamic study of ABBV-RGX-314 delivered subretinally using cGMP material produced by the company's NAVXpress™ bioreactor platform process.
The presentations include:
Title: Subretinal Delivery of ABBV-RGX-314 for Neovascular AMDAMD: A Phase II Pharmacodynamic Study
Presenter: Ashkan M. Abbey, M.D., F.A.S.R.S., F.A.A.O., Director of Clinical Research at Texas Retina Associates – Dallas and Clinical Assistant Professor of Ophthalmology at UT Southwestern Medical Center
Session Title: Wet AMDAMD Symposium 2
Date/Time: Sunday July 30, 8:00 am -8:06 am PDT
Type: Oral
Title: Suprachoroidal Delivery of ABBV-RGX-314 for Neovascular AMDAMD: Results from the Phase II AAVIATE Study
Presenter: David S. Boyer, M.D., Senior Partner, Retina-Vitreous Associates Medical Group in Southern California
Session Title: Wet AMD Symposium 2
Date/Time: Sunday July 30, 8:06 am -8:10 am PDT
Type: Oral
Title: Suprachoroidal Delivery of ABBV-RGX-314 Gene Therapy for Diabetic Retinopathy: The Phase II ALTITUDE Study
Presenter: Dilsher S. Dhoot, M.D.,Ophthalmologist at California Retinal Consultants
Session Title: Diabetic Retinopathy 4
Date/Time: Tuesday August 1, 9:45 am – 9:51 am PDT
Type: Oral
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from its internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Contact:
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
Company Codes: NASDAQ-NMS:RGNX
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.